SR-B1-targeted nanodelivery of anti-cancer agents

A promising new approach to treat triplenegative breast cancer

Rebecca Johnson, Nirupama Sabnis, Xiang Le Sun, Ruhani Ahluwalia, Andras G. Lacko

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fill a void toward the much needed development of improved treatment strategies for metastatic TNBC. The overall goal of this research was to evaluate the effectiveness of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for anti-TNBC drugs. Using lapatinib and valrubicin as components of the rHDL/drug complexes resulted in a significantly better performance of the NP-transported drugs compared with their free (unencapsulated) counterparts. The enhancement of the therapeutic effect and the protection of normal cells (cardiomyocytes) achieved via the rHDL NPs were likely due to the overexpression of the high-density lipoprotein (HDL) (scavenger receptor class B type 1 [SR-B1]) receptor by the TNBC cells.

Original languageEnglish
Pages (from-to)383-392
Number of pages10
JournalBreast Cancer: Targets and Therapy
Volume9
DOIs
StatePublished - 2 Jun 2017

Fingerprint

CD36 Antigens
Triple Negative Breast Neoplasms
HDL Lipoproteins
Breast Neoplasms
Nanoparticles
valrubicin
Neoplasms
Pharmaceutical Preparations
Cytoprotection
Therapeutic Uses
Research
Cardiac Myocytes
Hormones
Survival
Therapeutics

Keywords

  • Breast cancer
  • Lapatinib
  • RHDL nanoparticles
  • SR-B1 receptors
  • TNBC
  • Targeted drug delivery
  • Valrubicin

Cite this

@article{30c50081bc3d4765badd90094f9cc650,
title = "SR-B1-targeted nanodelivery of anti-cancer agents: A promising new approach to treat triplenegative breast cancer",
abstract = "Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30{\%}. The research presented here is intended to fill a void toward the much needed development of improved treatment strategies for metastatic TNBC. The overall goal of this research was to evaluate the effectiveness of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for anti-TNBC drugs. Using lapatinib and valrubicin as components of the rHDL/drug complexes resulted in a significantly better performance of the NP-transported drugs compared with their free (unencapsulated) counterparts. The enhancement of the therapeutic effect and the protection of normal cells (cardiomyocytes) achieved via the rHDL NPs were likely due to the overexpression of the high-density lipoprotein (HDL) (scavenger receptor class B type 1 [SR-B1]) receptor by the TNBC cells.",
keywords = "Breast cancer, Lapatinib, RHDL nanoparticles, SR-B1 receptors, TNBC, Targeted drug delivery, Valrubicin",
author = "Rebecca Johnson and Nirupama Sabnis and Sun, {Xiang Le} and Ruhani Ahluwalia and Lacko, {Andras G.}",
year = "2017",
month = "6",
day = "2",
doi = "10.2147/BCTT.S131038",
language = "English",
volume = "9",
pages = "383--392",
journal = "Breast Cancer: Targets and Therapy",
issn = "1179-1314",
publisher = "Dove Medical Press Ltd.",

}

SR-B1-targeted nanodelivery of anti-cancer agents : A promising new approach to treat triplenegative breast cancer. / Johnson, Rebecca; Sabnis, Nirupama; Sun, Xiang Le; Ahluwalia, Ruhani; Lacko, Andras G.

In: Breast Cancer: Targets and Therapy, Vol. 9, 02.06.2017, p. 383-392.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - SR-B1-targeted nanodelivery of anti-cancer agents

T2 - A promising new approach to treat triplenegative breast cancer

AU - Johnson, Rebecca

AU - Sabnis, Nirupama

AU - Sun, Xiang Le

AU - Ahluwalia, Ruhani

AU - Lacko, Andras G.

PY - 2017/6/2

Y1 - 2017/6/2

N2 - Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fill a void toward the much needed development of improved treatment strategies for metastatic TNBC. The overall goal of this research was to evaluate the effectiveness of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for anti-TNBC drugs. Using lapatinib and valrubicin as components of the rHDL/drug complexes resulted in a significantly better performance of the NP-transported drugs compared with their free (unencapsulated) counterparts. The enhancement of the therapeutic effect and the protection of normal cells (cardiomyocytes) achieved via the rHDL NPs were likely due to the overexpression of the high-density lipoprotein (HDL) (scavenger receptor class B type 1 [SR-B1]) receptor by the TNBC cells.

AB - Patients with triple-negative breast cancer (TNBC) have a considerably less favorable prognosis than those with hormone-positive breast cancers. TNBC patients do not respond to current endocrine treatment and have a 5-year survival prognosis of <30%. The research presented here is intended to fill a void toward the much needed development of improved treatment strategies for metastatic TNBC. The overall goal of this research was to evaluate the effectiveness of reconstituted high-density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for anti-TNBC drugs. Using lapatinib and valrubicin as components of the rHDL/drug complexes resulted in a significantly better performance of the NP-transported drugs compared with their free (unencapsulated) counterparts. The enhancement of the therapeutic effect and the protection of normal cells (cardiomyocytes) achieved via the rHDL NPs were likely due to the overexpression of the high-density lipoprotein (HDL) (scavenger receptor class B type 1 [SR-B1]) receptor by the TNBC cells.

KW - Breast cancer

KW - Lapatinib

KW - RHDL nanoparticles

KW - SR-B1 receptors

KW - TNBC

KW - Targeted drug delivery

KW - Valrubicin

UR - http://www.scopus.com/inward/record.url?scp=85020450180&partnerID=8YFLogxK

U2 - 10.2147/BCTT.S131038

DO - 10.2147/BCTT.S131038

M3 - Article

VL - 9

SP - 383

EP - 392

JO - Breast Cancer: Targets and Therapy

JF - Breast Cancer: Targets and Therapy

SN - 1179-1314

ER -